Muguruma K, Nakata B, Hirakawa K, Yamashita Y, Onoda N, Inoue T, Matsuoka T, Kato Y, Sowa M
First Dept. of Surgery, Osaka City University Medical School.
Gan To Kagaku Ryoho. 1998 Apr;25 Suppl 3:400-3.
This study was performed to estimate p53 and Bax overexpression as a predictor of the response to chemotherapy of patients with gastric cancer. The subjects were 20 patients with stage IV gastric cancer and 3 with locally recurrent lesions treated with 5-fluorouracil (5-FU) and low-dose cisplatin (CDDP) for 4 weeks. Of the total 23 patients, there were 10 responders: 2 showing complete response (CR) and 8, partial response (PR). Carcinoma biopsy specimens of all were obtained endoscopically with anti-p53 and anti-Bax antibodies. Of the 10 responders, 7 were in the negative p53 staining group, while of the 13 non-responders, 11 were in the positive p53 staining group (p = 0.013). But no correlation was demonstrated between the chemotherapeutic effect and Bax staining alone. Moreover, among the p-53-positive cases, the patients with Bax-negative tumors were all chemoresistant. Therefore, immunohistochemical identification of p-53 and Bax prior to chemotherapy may be a useful predictor for choice of non-responders to chemotherapy.
本研究旨在评估p53和Bax的过表达情况，以此作为胃癌患者化疗反应的预测指标。研究对象为20例IV期胃癌患者和3例局部复发病灶患者，采用5-氟尿嘧啶（5-FU）和低剂量顺铂（CDDP）进行为期4周的治疗。23例患者中，有10例有反应：2例完全缓解（CR），8例部分缓解（PR）。所有患者均通过内镜获取癌组织活检标本，并使用抗p53和抗Bax抗体进行检测。10例有反应的患者中，7例在p53染色阴性组；而13例无反应的患者中，11例在p53染色阳性组（p = 0.013）。但单独的Bax染色与化疗效果之间未显示出相关性。此外，在p53阳性病例中，Bax阴性肿瘤患者均对化疗耐药。因此，化疗前对p53和Bax进行免疫组化鉴定可能有助于预测哪些患者对化疗无反应。
